Rodolfo Staico

TL;DR: In this article, the safety and efficacy of sirolimus-coated BX Velocity stents were evaluated in 30 patients with angina pectoris electively treated with two different formulations of SIROlimuscoated stents (slow release and fast release).

TL;DR: In patients with stable coronary artery disease or low-risk ACS treated with zotarolimus-eluting stents, 3 months of dual antiplatelet therapy was noninferior to 12 months for NACCE, without significantly increasing the risk of stent thrombosis.

TL;DR: Investigation of the incidence and long-term clinical consequences of late ISA after implantation of sirolimus- (SES) or paclitaxel-eluting stent (PES) in a non-selected population found it related to regional vessel positive remodelling.

TL;DR: Implantation of 17-beta-estradiol-eluted BiodVysio stents appears feasible and safe, showing low rates of binary restenosis and revascularization, and warrant further confirmation with a large, randomized multicenter trial.

TL;DR: Intravascular ultrasound assessment late after the ASO revealed proximal eccentric intimal thickening in most of the studied vessels, which suggests the development of early atherosclerosis in the reimplanted coronary arteries, which may have a role in the genesis of late coronary events.